Robert S. Breuil
Net Worth
Last updated:
What is Robert S. Breuil net worth?
The estimated net worth of Mr. Robert S. Breuil is at least $1,792,910 as of 14 Mar 2023. He has earned $28,590 from insider trading and has received compensation worth at least $1,764,320 in Graybug Vision, Inc..
What is the salary of Robert S. Breuil?
Mr. Robert S. Breuil salary is $441,080 per year as Chief Financial Officer in Graybug Vision, Inc..
How old is Robert S. Breuil?
Mr. Robert S. Breuil is 63 years old, born in 1962.
What stocks does Robert S. Breuil currently own?
As insider, Mr. Robert S. Breuil owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Graybug Vision, Inc. (GRAY) | Chief Financial Officer | 20,529 | $0 | $0 |
What does Graybug Vision, Inc. do?
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Robert S. Breuil insider trading
Graybug Vision, Inc.
Mr. Robert S. Breuil has made 2 insider trades between 2021-2023, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 121,217 units of GRAY stock on 3 Mar 2023. As of 14 Mar 2023 he still owns at least 20,529 units of GRAY stock.
Graybug Vision key executives
Graybug Vision, Inc. executives and other stock owners filed with the SEC:
- Dr. Frederic Guerard Pharm.D. (53) Pres, Chief Executive Officer & Director
- Dr. Gerald D. Cagle Ph.D. (81) Senior Advisor, Head of Bus. Devel. & Director
- Dr. Parisa Zamiri M.D., Ph.D. (60) Chief Medical Officer
- Mr. Robert S. Breuil (63) Chief Financial Officer